Filters

Pp-196 manufacturers

Filters

None products found

pp-196

Oral solution

Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Urinary tract infections (UTI) caused by E. coli — including multidrug-resistant strains; Clinical stage: Phase 2/3 — ELIMINATE trial ongoing Modality: Biological (CRISPR-Cas3-engineered precision bacteriophage cocktail — NBE) Mechanism / Target: Cocktail of engineered lytic bacteriophages containing CRISPR-Cas3 bacterial chromosome-degrading payload; specifically targets and eliminates E. coli (including MDR strains) without disrupting commensal microbiome; CRISPR-Cas3 is mutation-resistant (degrades entire chromosome) Route / form: Oral / intravesical delivery Differentiation: First CRISPR-engineered precision phage therapy in Phase 2/3; targets multidrug-resistant E. coli UTI — a major antibiotics-resistance crisis;
Manufacturer #39335
US-based clinical-stage biotech developing Rx engineered biotherapeutics for drug-resistant bacterial infections and related areas. A proprietary precision platform advances lead programs through mid-stage clinical trials. Operates global development partnerships addressing antimicrobial resistance.

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.